Sanofi has been granted marketing authorisation for Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis in certain adult patients.
The decision was widely anticipated, after the EMA’s advisory committee delivered a positive opinion on the therapy in July.
The drug was approved in this indication in the USA in March.
Dupilumab is a human monoclonal antibody that is designed to specifically inhibit overactive signaling of two proteins, IL-4 and IL-13.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze